source
- Replimune's melanoma virus therapy wins FDA advisory committee vote after two rejectionsReplimune's oncolytic virus RP1, also called vusolimogene oderparepvec and Tudriqev, has been rejected twice by the FDA. Today an advisory committee voted 10 to 3 that the candidate shows enough ef…
- Trump administration delays start of first pharma tariff wave originally set for July 31President Donald Trump's administration had scheduled the first set of pharmaceutical tariffs to begin on July 31, but the rollout has been postponed. A White House official said the implementation…